Lightlake Therapeutics Inc. Appoints Board Member as New Chief Financial Officer
LONDON, Nov. 29, 2012 /PRNewswire/ -- Lightlake Therapeutics Inc. (LLTP) (the "Company" or "Lightlake"), an early stage biopharmaceutical company developing modern addiction treatments based on its expertise using opioid antagonists, announced today that it has appointed Mr. Kevin Pollack, who has been a member of Lightlake's Board of Directors since April 2012, as the Company's new Chief Financial Officer.
"It has been a privilege to work with Kevin since he joined our Board and when we look to our future as a company, we believe now is the appropriate time to appoint him as our CFO," said Dr. Roger Crystal, Chief Executive of Lightlake. "Kevin has demonstrated to us his expertise in both finance and strategy while serving on our Board, and by appointing him as our CFO we believe he will be in a better position to utilize his talents as we strive to build a platform of biopharmaceutical solutions to common addictions and related disorders."
In addition to his duties at Lightlake, Mr. Pollack is also a Managing Director at Paragon Capital, a private investment firm focused primarily on investing in U.S.-listed companies. He also serves as President of Short Hills Capital LLC, where he provides a range of advisory services to investors, asset management firms, institutions, and companies. Mr. Pollack currently sits on the Board of Directors of MagneGas Corporation, the developer of a technology that converts liquid waste into a hydrogen-based metal working fuel and natural gas alternative, as well as Pressure BioSciences, Inc., which develops, markets and sells proprietary laboratory instrumentation and associated consumables based on Pressure Cycling Technology.
Mr. Pollack's past experiences include working as an investment banker at Banc of America Securities LLC, focusing on corporate finance and on mergers and acquisitions. He started his career at Sidley Austin LLP (formerly Brown & Wood LLP) as a securities attorney focusing on corporate finance and on mergers and acquisitions. He graduated magna cum laude from The Wharton School of the University of Pennsylvania and received a dual J.D./M.B.A. from Vanderbilt University, where he graduated with Beta Gamma Sigma honors.
About Lightlake Therapeutics Inc.
Lightlake Therapeutics Inc. is a developing biopharmaceutical company aiming to build a platform of biopharmaceutical solutions to common addictions and related disorders. Currently, the Company is focused on providing a safe, effective and simple treatment for patients who are obese or overweight as a result of Binge Eating Disorder in addition to those patients suffering from Bulimia Nervosa. Lightlake recently acquired patents that will allow it to widen its product pipeline to address patients with addictions to opioid painkillers, methadone, cocaine and amphetamine. The Company anticipates launching a development program for each of these purposes in the future.
Safe Harbor
This press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied or inferred by these forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "could," "would," "expects," "plans," "intends," "anticipates," "believes," estimates," "predicts," "projects," "potential" or "continue" or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. Actual events or results may differ materially. In evaluating these statements, you should specifically consider various factors. These and other factors may cause our actual results to differ materially from any forward- looking statement. We undertake no obligation to update any of the forward-looking statements after the date of this presentation to conform those statements to reflect the occurrence of unanticipated events, except as required by applicable law.
Contact:
Investor
Mr. Kevin Fickle
President
NUWA Group LLC
Tel: +1-925-330-8315
Email: kevin@nuwagroup.com
Company
Dr. Roger Crystal
Lightlake Therapeutics Inc.
Tel: +44(0)-203-617-8739
Email: roger.crystal@lightlaketherapeutics.com
SOURCE Lightlake Therapeutics Inc.